BCL2 and acute myeloid leukemia: Notably, a particularly favorable response was seen in the subgroup of patients with IDH-mutant AML using a combination of BCL2 inhibitor venetoclax and azacitidine (12-month OS 66.8% in venetoclax and azacitidine versus 35.7% in the azacitidine only group) [38].